title: Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia.
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address: daniel.landsburg@uphs.upenn.edu.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Landsburg
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
authors.forename: Dan T
authors.initials: DT
authors.lastname: Vogl
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
authors.forename: John P
authors.initials: JP
authors.lastname: Plastaras
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D019653:Myeloablative Agonists; D008558:Melphalan
keywords: Allogeneic stem cell transplantation; Melphalan; Plasma cell leukemia; Total body irradiation